How to Buy Lyell Immunopharma, Inc. Common Stock (LYEL) Stock

Where to buy LYEL

13 brokers in our matrix offer LYEL. Verify availability and current fees with each broker before trading.

Broker	Commission	Fractional	Extended	Overnight	Options	OTC access
Charles Schwab (thinkorswim)Review	$0	Schwab Stock Slices, S&P 500 only, ≥ $5/slice, up to 30 at once		~1,130	$0.65	Most (3/5)
E*TRADE (Morgan Stanley)Review	$0 listed			~20	$0.65	Most (4/5)
FidelityReview	$0	Stocks by the Slice, 7,000+ stocks/ETFs, from $1			$0.65	Partial (2+0)
FirstradeReview	$0	~4,000+ tickers, ≥ $5		~1,200	$0	Most (4/5)
Interactive BrokersReview	$0 (Lite) / per-share (Pro)			~10,000	per-contract pricing	Full
Merrill EdgeReview	$0				$0.65	Most (3/5)
MoomooReview	$0				$0	Limited only
Public.comReview	$0				rebate model	Limited only
RobinhoodReview	$0	≥ $1 stocks, market cap ≥ $25M		~1,134	$0	None
SoFi Active InvestingReview	$0				$0	Partial (1+2)
tastytradeReview	$0 stocks				$1.00 open, $0 close (capped at $10 per leg)	Limited only
TradeStationReview	$0 listed				$0.50 / $0.60	Most (4/5)
WebullReview	$0				$0	Limited only

24-Hour / Overnight trading

LYEL may be eligible for overnight trading via Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), Webull, Moomoo, Firstrade. Each broker maintains its own eligibility list — confirm before placing an order.

About Lyell Immunopharma, Inc. Common Stock

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Sector

PHARMACEUTICAL PREPARATIONS

Employees

161

Headquarters

SOUTH SAN FRANCISCO, CA

Listed

2021-06-17

Market cap

$401.81M

Frequently asked

Where can I buy Lyell Immunopharma, Inc. Common Stock (LYEL)?

LYEL is offered by 13 brokers in our matrix, including Charles Schwab (thinkorswim), E*TRADE (Morgan Stanley), Fidelity, Firstrade, Interactive Brokers. Compare commissions, fractional eligibility, and overnight availability in the broker matrix above.

Can I buy LYEL after hours or overnight?

Yes. LYEL is on the 24-hour eligibility list for Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), and others. Overnight sessions route through ATSs with wider spreads and limit-orders only.

Does Robinhood offer LYEL?

Yes. Robinhood offers LYEL as a regular exchange-listed security.

Does Fidelity offer LYEL?

Yes. Fidelity offers LYEL as a regular exchange-listed security.

Does Webull offer LYEL?

Yes. Webull offers LYEL as a regular exchange-listed security.

Is LYEL optionable?

Yes. LYEL has listed options contracts. Per-contract pricing varies by broker — see the Options column in the matrix.

Is there a tokenized version of LYEL?

Not in our current dataset. The tokenized stock universe (Kraken xStocks, Binance Alpha/Ondo, Robinhood EU, Hyperliquid HIP-3) is expanding quickly — we refresh quarterly.

Can I buy a fractional share of LYEL?

Yes. Multiple brokers in the matrix support fractional shares for LYEL — see the Fractional column above for per-broker eligibility and minimums.